INVO Fertility Announces Second Quarter 2025 Financial Results
INVO Fertility (NASDAQ:IVF) reported its Q2 2025 financial results, achieving record quarterly revenue of $1.86 million, up 1% year-over-year. The company's consolidated clinic revenue from Atlanta and Madison locations increased 1% to $1.83 million, while total revenue including equity method clinics rose 2% to $2.19 million.
Key operational highlights include Wisconsin Fertility Institute's recognition on Newsweek's Best Fertility Clinics list, launch of telehealth capabilities, and addition of Platelet-Rich Plasma therapy services. The company received a patent allowance for its modified INVOcell device, extending protection through 2040. INVO completed the divestiture of NAYA Therapeutics, retaining a minority stake while refocusing on core fertility operations.
However, the company reported a net loss from continuing operations of $(3.2) million, compared to $(2.2) million in Q2 2024, with Adjusted EBITDA at $(587,230).
INVO Fertility (NASDAQ:IVF) ha comunicato i risultati finanziari del secondo trimestre 2025, registrando un fatturato trimestrale record di $1,86 milioni, in crescita dell'1% rispetto allo stesso periodo dell'anno precedente. I ricavi consolidati delle cliniche di Atlanta e Madison sono aumentati dell'1%, arrivando a $1,83 milioni, mentre il totale dei ricavi comprensivo delle cliniche valutate con il metodo del patrimonio netto è salito del 2% a $2,19 milioni.
I principali progressi operativi comprendono il riconoscimento del Wisconsin Fertility Institute nella classifica di Newsweek delle migliori cliniche per la fertilità, il lancio dei servizi di telemedicina e l'introduzione della terapia con plasma ricco di piastrine. La società ha inoltre ottenuto l'accettazione di un brevetto per una versione modificata del dispositivo INVOcell, estendendo la protezione fino al 2040. INVO ha completato la cessione di NAYA Therapeutics, mantenendo una partecipazione di minoranza e concentrandosi nuovamente sulle attività principali nel campo della fertilità.
Tuttavia, la società ha riportato una perdita netta dalle operazioni continuative di $(3,2) milioni, rispetto a $(2,2) milioni nel Q2 2024, con un EBITDA rettificato di $(587.230).
INVO Fertility (NASDAQ:IVF) informó sus resultados financieros del segundo trimestre de 2025, alcanzando ingresos trimestrales récord de $1.86 millones, un aumento del 1% interanual. Los ingresos consolidados de las clínicas de Atlanta y Madison crecieron un 1% hasta $1.83 millones, mientras que los ingresos totales, incluyendo clínicas valoradas por el método de participación, aumentaron un 2% hasta $2.19 millones.
Entre los hitos operativos se encuentran el reconocimiento del Wisconsin Fertility Institute en la lista de mejores clínicas de fertilidad de Newsweek, el lanzamiento de capacidades de telemedicina y la incorporación de terapia con plasma rico en plaquetas. La compañía recibió la aprobación de una patente para una versión modificada del dispositivo INVOcell, extendiendo la protección hasta 2040. INVO completó la desinversión de NAYA Therapeutics, manteniendo una participación minoritaria y reenfocándose en sus operaciones centrales de fertilidad.
No obstante, la empresa reportó una pérdida neta de las operaciones continuas de $(3.2) millones, frente a $(2.2) millones en el Q2 de 2024, con un EBITDA ajustado de $(587,230).
INVO Fertility (NASDAQ:IVF)는 2025년 2분기 실적을 발표하며 분기 역대 최고 매출 $1.86백만을 기록해 전년 동기 대비 1% 증가했습니다. 애틀랜타 및 매디슨 지점의 연결 클리닉 매출은 1% 증가해 $1.83백만을 기록했으며, 지분법 적용 클리닉을 포함한 총매출은 2% 증가해 $2.19백만이었습니다.
주요 운영 성과로는 위스콘신 불임연구소가 Newsweek의 베스트 불임 클리닉 목록에 선정된 점, 원격진료(텔레헬스) 서비스 도입, 그리고 혈소판 풍부 혈장(Platelet-Rich Plasma) 치료 서비스 추가가 포함됩니다. 또한 수정된 INVOcell 장치에 대한 특허 허가를 받아 보호 기간을 2040년까지 연장했습니다. INVO는 NAYA Therapeutics의 매각을 완료했으며 소수 지분을 유지한 채 핵심 불임 사업에 재집중하고 있습니다.
다만, 지속 영업에서의 순손실은 $(3.2)백만으로 Q2 2024의 $(2.2)백만에 비해 확대되었고, 조정 EBITDA는 $(587,230)입니다.
INVO Fertility (NASDAQ:IVF) a publié ses résultats du deuxième trimestre 2025, réalisant un chiffre d'affaires trimestriel record de 1,86 M$, en hausse de 1% sur un an. Les revenus consolidés des cliniques d'Atlanta et de Madison ont augmenté de 1% pour atteindre 1,83 M$, tandis que le chiffre d'affaires total, incluant les cliniques en mise en équivalence, a progressé de 2% pour atteindre 2,19 M$.
Parmi les faits opérationnels majeurs figurent la reconnaissance du Wisconsin Fertility Institute dans le classement des meilleures cliniques de fertilité de Newsweek, le lancement de services de télésanté et l'ajout de la thérapie par plasma riche en plaquettes. La société a obtenu l'acceptation d'un brevet pour une version modifiée du dispositif INVOcell, prolongeant la protection jusqu'en 2040. INVO a finalisé la cession de NAYA Therapeutics, conservant une participation minoritaire et se recentrant sur ses activités principales en matière de fertilité.
Cependant, la société a enregistré une perte nette provenant des activités poursuivies de $(3,2) M, contre $(2,2) M au T2 2024, avec un EBITDA ajusté de $(587 230).
INVO Fertility (NASDAQ:IVF) meldete seine Finanzergebnisse für das 2. Quartal 2025 und erzielte einen rekordverdächtigen Quartalsumsatz von $1,86 Millionen, ein Plus von 1% gegenüber dem Vorjahr. Die konsolidierten Klinikumsätze aus den Standorten Atlanta und Madison stiegen um 1% auf $1,83 Millionen, während die Gesamterlöse einschließlich der equity-bewerteten Kliniken um 2% auf $2,19 Millionen zunahmen.
Zu den wichtigsten operativen Meilensteinen zählen die Aufnahme des Wisconsin Fertility Institute in Newsweeks Liste der besten Fruchtbarkeitskliniken, die Einführung von Telemedizin-Funktionen und die Aufnahme einer Platelet-Rich Plasma-Therapie ins Angebot. Das Unternehmen erhielt einen Patenterlass für eine modifizierte INVOcell-Vorrichtung, wodurch der Schutz bis 2040 verlängert wird. INVO schloss die Veräußerung von NAYA Therapeutics ab, behielt eine Minderheitsbeteiligung und richtet den Fokus wieder auf das Kerngeschäft im Bereich Fruchtbarkeit.
Dennoch verzeichnete das Unternehmen einen Nettoverlust aus fortgeführten Geschäftsbereichen in Höhe von $(3,2) Millionen, gegenüber $(2,2) Millionen im Q2 2024, bei einem bereinigten EBITDA von $(587.230).
- Record quarterly revenue of $1.86M, up 1% year-over-year
- Wisconsin Fertility Institute recognized on Newsweek's Best Fertility Clinics 2025 list
- New patent allowance for INVOcell device extends protection through 2040
- Successful expansion of services with telehealth and PRP therapy offerings
- Strategic divestiture of NAYA Therapeutics allows focus on core fertility operations
- Net loss increased to $(3.2M) from $(2.2M) year-over-year
- Adjusted EBITDA declined to $(587,230) from $(509,623)
- Minimal revenue growth of only 1-2% across operations
Insights
INVO Fertility showed modest 1% revenue growth but widening losses with operating improvements yet to impact bottom line.
INVO Fertility posted record quarterly revenue of
More concerning is the substantial deterioration in profitability, with net losses increasing by
The divestiture of NAYA Therapeutics marks a strategic refocusing on INVO's core fertility operations, which could improve operational efficiency in the long run. However, this restructuring hasn't yet translated to financial improvement. The company's introduction of telehealth capabilities and Platelet-Rich Plasma therapy services in Wisconsin represents attempts to diversify revenue streams and expand market reach without significant capital investment.
The patent allowance for a modified INVOcell device extending protection through 2040 provides long-term intellectual property security, but the immediate financial impact appears minimal given current performance metrics. Management's emphasis on maintaining an "efficient and scalable operating structure" suggests cost-cutting measures may be forthcoming, as the current trajectory of widening losses isn't sustainable without additional financing.
SARASOTA, Fla., Aug. 14, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced second quarter 2025 financial results.
Q2 2025 Financial Highlights (all metrics compared to Q2 2024 unless otherwise noted)
- Revenue was
$1,863,654 , an increase of1% compared to$1,836,597 , a new quarterly record for the Company. - Consolidated clinic revenue from the Company's INVO Center in Atlanta, Georgia, and fertility clinic in Madison, Wisconsin, increased
1% to$1,832,094 , compared to$1,807,921. - Revenue from all clinics, including both consolidated and equity method clinics, was
$2,188,893 , an increase of2% compared to$2,141,229. - Net loss from continuing operations was
$(3.2) million compared to$(2.2) million . - Adjusted EBITDA (see table included) was
$(587,230) compared to$(509,623) in the prior year.
Operational and other Highlights
- Wisconsin Fertility Institute recognized on Newsweek’s List of America’s Best Fertility Clinics for 2025. The ranking lists the top facilities defined as a fertility clinic and advanced reproductive technologies (ART) provider by the Centers for Disease Control and Prevention (CDC).
- Launched telehealth capabilities at the Wisconsin clinic to expand its geographic reach and to provide patients with expert fertility care in a convenient manner.
- Added Platelet-Rich Plasma (PRP) therapy to its comprehensive suite of fertility services at the Wisconsin clinic. This cutting-edge treatment offers additional options for individuals and couples facing fertility challenges, further expanding the clinic’s commitment to innovative, patient-centered care.
- Received a notice of allowance on a new patent for a modified version of the Company’s proprietary INVOcell device. The new patent extends intellectual property protection on the Company’s INVOcell device through 2040 based on a modified design which reflects feedback from leading embryologists to simplify use of the device.
- Expanded clinical and embryology training support and improved pricing for its innovative INVOcell® technology. This underscores the Company’s dual mission as an innovator of cutting-edge fertility solutions and a provider of compassionate, patient-centered clinical care.
- Completed divestiture of NAYA Therapeutics, Inc. (“NAYA”).
Return to Focus on Fertility Operations
On June 2, 2025, the Company completed the divestiture of a majority stake in NAYA. The Company has retained a minority position in NAYA that offers the potential to benefit from NAYA’s ongoing clinical development of its bifunctional antibodies. The revised corporate structure enables both businesses to focus on their respective opportunities and operations, with the existing Company management team and board leading the public company (INVO Fertility, Inc.). NAYA has returned to being a privately held biotechnology company led by a separate management team and board.
Management Commentary
“Following the decision in April 2025 to refocus exclusively on our fertility operations, we have made progress in driving growth and innovation in our existing operations and in taking key steps required for continued operating improvement moving forward,” commented Steve Shum, CEO of INVO Fertility. “Working collectively with our clinic operators, we have expanded our service offering to include new telehealth options and PRP therapy, demonstrating our commitment to quality patient-centered care. We ramped up our training support for our INVOcell® technology with clinicians and embryologists, in pursuit of our dual mission as an innovator of cutting-edge fertility solutions and healthcare services provider.”
“We remain committed to our goal of maintaining a highly efficient and scalable operating structure while layering in complementary and accretive revenue-generating businesses and technologies as we move forward.”
Use of Non-GAAP Measure
Included in this press release is a reconciliation of Adjusted EBITDA, which does not include the loss from NAYA or the corresponding merger-related costs. Additional financial tables are included in the Company’s Form 10-Q, which can be found on the Company’s website at invofertility.com/sec-filings or at sec.gov.
Adjusted EBITDA is a non-GAAP measure. This measure is not intended to be a substitute for those financial measures reported in accordance with GAAP. Adjusted EBITDA has been included because management believes that, when considered together with the GAAP figures, it provides meaningful information related to our operating performance and liquidity and can enhance an overall understanding of financial results and trends. Adjusted EBITDA may be calculated by us differently than other companies that disclose measures with the same or similar terms. See our attached financials for a reconciliation of this non-GAAP measure to the nearest GAAP measure.
About INVO Fertility
We are a healthcare services fertility company dedicated to expanding access to assisted reproductive technology (“ART”) care to patients in need. Our principal commercial strategy is focused on building, acquiring, and operating fertility clinics, including “INVO Centers” dedicated primarily to offering the intravaginal culture (“IVC”) procedure enabled by our INVOcell® medical device (“INVOcell”) and US-based, profitable in vitro fertilization (“IVF”) clinics. We have two operational INVO Centers in the United States and one IVF clinic. We also continue to engage in the sale and distribution of INVOcell to third-party owned and operated fertility clinics. INVOcell is a proprietary and revolutionary medical device, and the first to allow fertilization and early embryo development to take place in vivo within the woman's body. The IVC procedure provides patients with a more connected, intimate, and affordable experience in comparison to other ART treatments. We believe the IVC procedure can deliver comparable results at a fraction of the cost of traditional IVF and is a significantly more effective treatment than intrauterine insemination. For more information, please visit invofertility.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties, and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events, or otherwise.
For more information, please contact:
INVO Fertility, Inc.
Steve Shum, CEO
978-878-9505
sshum@invobio.com
Investor Contact
Lytham Partners, LLC
Robert Blum
602-889-9700
INVO@lythampartners.com
| INVO FERTILITY, INC. | |||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| (UNAUDITED) | |||||||||||||||
| For the Three Months Ended | For the Six Months Ended | ||||||||||||||
| June 30, | June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Revenue: | |||||||||||||||
| Clinic revenue | $ | 1,832,094 | $ | 1,807,921 | $ | 3,453,647 | $ | 3,345,120 | |||||||
| Product revenue | 31,560 | 28,676 | 47,192 | 67,763 | |||||||||||
| Total revenue | 1,863,654 | 1,836,597 | 3,500,839 | 3,412,883 | |||||||||||
| Operating expenses | |||||||||||||||
| Cost of revenue | 1,093,603 | 861,648 | 2,138,532 | 1,711,882 | |||||||||||
| Selling, general and administrative expenses | 2,193,049 | 2,647,524 | 3,750,371 | 4,088,110 | |||||||||||
| Research and development expenses | - | - | - | 4,880 | |||||||||||
| Impairment loss | 1,397,353 | - | 1,397,353 | - | |||||||||||
| (Gain) loss on disposal of fixed assets | (50,000 | ) | - | 511,663 | |||||||||||
| Depreciation and amortization | 169,737 | 230,338 | 404,199 | 457,298 | |||||||||||
| Total operating expenses | 4,853,742 | 3,689,510 | 7,690,455 | 6,773,833 | |||||||||||
| Loss from operations | (2,990,088 | ) | (1,852,913 | ) | (4,189,616 | ) | (3,360,950 | ) | |||||||
| Other income (expense): | |||||||||||||||
| Gain (loss) from equity method joint ventures | (19,911 | ) | 17,846 | (4,815 | ) | 17,950 | |||||||||
| Gain on lease termination | - | - | - | 94,551 | |||||||||||
| Loss on debt extinguishment | (692,270 | ) | (40,491 | ) | (692,270 | ) | (40,491 | ) | |||||||
| Gain on settlement | 714,500 | - | 714,500 | - | |||||||||||
| Interest expense | (221,325 | ) | (369,612 | ) | (529,164 | ) | (550,907 | ) | |||||||
| Total other income (expense) | (219,006 | ) | (390,257 | ) | (511,749 | ) | (478,897 | ) | |||||||
| Net loss from continuing operations before income taxes | (3,209,094 | ) | (2,245,170 | ) | (4,701,365 | ) | (3,839,847 | ) | |||||||
| Income taxes | - | - | - | 1,836 | |||||||||||
| Net loss from continuing operations | (3,209,094 | ) | (2,245,170 | ) | (4,701,365 | ) | (3,841,683 | ) | |||||||
| Discontinued operations | |||||||||||||||
| Loss on disposal of NTI | (1,534,517 | ) | - | (1,534,517 | ) | - | |||||||||
| Loss on discontinued operations of NTI | (541,247 | ) | - | (16,452,562 | ) | - | |||||||||
| Net loss | (5,284,858 | ) | (2,245,170 | ) | (22,688,444 | ) | (3,841,683 | ) | |||||||
| Loss from continuing operations per share | |||||||||||||||
| Basic | $ | (7.95 | ) | $ | (22.39 | ) | $ | (15.72 | ) | $ | (45.01 | ) | |||
| Diluted | $ | (7.95 | ) | $ | (22.39 | ) | $ | (15.72 | ) | $ | (45.01 | ) | |||
| Loss from discontinued operations per common share | |||||||||||||||
| Basic | $ | (1.49 | ) | $ | - | $ | (55.00 | ) | $ | - | |||||
| Diluted | $ | (1.49 | ) | $ | - | $ | (55.00 | ) | $ | - | |||||
| Loss per common share: | |||||||||||||||
| Basic | $ | (13.30 | ) | $ | (22.39 | ) | $ | (75.85 | ) | $ | (45.01 | ) | |||
| Diluted | $ | (13.30 | ) | $ | (22.39 | ) | $ | (75.85 | ) | $ | (45.01 | ) | |||
| Weighted average number of common shares outstanding: | |||||||||||||||
| Basic | 397,440 | 100,276 | 299,114 | 85,360 | |||||||||||
| Diluted | 397,440 | 100,276 | 299,114 | 85,360 | |||||||||||
| Adjusted EBITDA | |||||||
| Three Months Ended | |||||||
| June 30 | |||||||
| 2025 | 2024 | ||||||
| Net loss from continuing operations | $ | (3,209,094 | ) | $ | (2,245,170 | ) | |
| Interest expense | 177,472 | 118,640 | |||||
| Amortization of debt discount | 43,853 | 250,972 | |||||
| Tax expense (benefit) | - | - | |||||
| Stock-based compensation | 668,805 | 1,031,071 | |||||
| Stock option expense | 11,875 | 69,035 | |||||
| Non cash compensation for services | 45,000 | 45,000 | |||||
| Loss on disposal of fixed assets | - | (50,000 | ) | ||||
| Loss from debt extinguishment | 692,270 | 40,491 | |||||
| Gain on settlement of liability | (714,500 | ) | - | ||||
| Impairment loss | 1,397,353 | - | |||||
| Merger-related costs | 130,000 | - | |||||
| Depreciation and amortization | 169,736 | 230,338 | |||||
| Adjusted EBITDA | $ | (587,230 | ) | $ | (509,623 | ) | |
FAQ
What were INVO Fertility's (IVF) Q2 2025 earnings results?
How did INVO Fertility's clinic revenue perform in Q2 2025?
What strategic changes did INVO Fertility make in 2025?
What new developments were announced for INVO Fertility's INVOcell device?
What recognition did INVO Fertility receive in 2025?
